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Elimination of superfluous or mutated somatic cells is provided by various mechanisms including apoptosis, and deregulation of apop-
totic signaling pathways contributes to oncogenesis. 40 years have passed since the term “apoptosis”  was introduced by Kerr et al. 
in 1972; among the programmed cell death, a variety of therapeutic strategies especially targeting apoptotic pathways have been in-
vestigated. Alternative precursor messenger RNA splicing, by which the process the exons of pre-mRNA are spliced in different ar-
rangements to produce structurally and functionally distinct mRNA and proteins, is another field in progress, and it has been recognized 
as one of the most important mechanisms that maintains genomic and functional diversity. A variety of apoptotic genes are regulated 
through alternative pre-mRNA splicing as well, some of which have important functions as pro-apoptotic and anti-apoptotic factors. 
In this article we summarized splice variants of some of the apoptotic genes including BCL2L1, BIRC5, CFLAR, and MADD, as well 
as the regulatory mechanisms of alternative splicing of these genes. If the information of the apoptosis and aberrant splicing in each 
of malignancies is integrated, it will become possible to target proper variants for apoptosis, and the trans-elements themselves can 
become specific targets of cancer therapy as well. This article is part of a Special Issue entitled “Apoptosis: Four Decades Later”.
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INTRODUCTION
Elimination of superfluous or mutated somatic cells 
is provided by various mechanisms including apoptosis 
[1], and deregulation of apoptotic signaling pathways 
contributes to oncogenesis. It was 40 years ago when 
Kerr, Wyllie, and Currie coined the term “apoptosis” 
to describe a special form of programmed cell death 
and published their original article on apoptosis [2]. 
Since that time the concept of apoptosis has con-
tributed much to the various fields of biology and 
medicine especially in cancer research, and a variety 
of therapeutic strategies especially targeting apoptotic 
pathways have been investigated. On the other hand, 
alternative precursor messenger RNA (pre-mRNA) 
splicing, by which the process the exons of pre-mRNA 
are spliced in different arrangements to produce struc-
turally and functionally distinct mRNA and proteins, 
is another field in progress [3]. After the completion 
of the Human Genome Project in 2004, alternative 
pre-mRNA splicing has been recognized as one of the 
most important mechanisms that maintains genomic 
and functional diversity. A variety of apoptotic genes 
are regulated through alternative pre-mRNA spli-
cing as well, some of which have important functions 
as pro-apoptotic and anti-apoptotic factors. In this 
article, we summarized splice variants of some of the 
apoptotic genes as well as the regulatory mechanisms 
of alternative splicing of those genes.
APOPTOTIC PATHWAY 
There are two main pathways in apoptosis: the 
death receptor-mediated apoptotic pathway (extrinsic 
pathway) and the mitochondrial-mediated apoptotic 
pathway (intrinsic pathway) (Fig. 1). 
Fig. 1. A scheme of apoptotic pathway 
The death receptor-mediated apoptotic path-
way is initiated when tumor necrosis factor (TNF), 
TNF-related apoptosis-inducing ligand (TRAIL, also 
known as apolipoprotein-2L (APO-2L)) or FAS ligand 
(APO-1) bind to their receptors (TNFR, TRAIL-R and 
FAS, respectively), in association with adaptor mol-
ecules such as FAS-associated death domain (FADD) 
or TNFR-associated death domain (TRADD), and ini-
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tiator caspases-8 and -10 are cleaved and activated, 
thus resulting in the activation of executor caspases-3, 
-6 and -7 and culminating in apoptosis. On the other 
hand, the mitochondrial-mediated apoptotic pathway 
is initiated when pro-apoptotic proteins release free 
cytosolic cytochrome c. Once released, cytochrome 
c promotes the assembly of a caspase-activating 
complex termed the apoptosome, which includes 
apoptosis-activating factor-1 (APAF1), dATP, and 
pro-caspase-9. The apoptosome activity functionally 
corresponds to the activity of caspase-9, and it acti-
vates executor caspases-3, -6, and -7, thus inducing 
apoptosis. The inhibitor of apoptosis protein (IAP) 
proteins such as cIAP1, cIAP2, and XIAP can prevent 
the proteolytic processing of pro-caspases-3, -6, and 
-7 by blocking the cyto chrome c-induced activation 
of pro-caspase-9 in the intrinsic pathway; in contrast, 
these IAP proteins do not act in the extrinsic pathway 
[4]. APAF1/cytochrome c-independent and second 
mitochondria-derived activator of caspases (Smac)/
direct IAP-binding protein with low PI (DIABLO)-depen-
dent induction of apoptosis have also been reported. 
Alternative models of programmed cell death have 
been proposed, but still remain to be further clarified, 
including autophagy, paraptosis, mitotic catastro-
phe, and the descriptive model of apoptosis-like and 
necrosis-like programmed cell death [1, 5].
ALTERNATIVE PRE-mRNA SPLICING 
Pre-mRNA splicing is a mechanism that removes 
introns from pre-mRNA and binds exons, eventu-
ally generating mature mRNA (Fig. 2). The process 
of pre-mRNA splicing is regulated by two elements: 
cis-elements and trans-elements, and the cis-ele-
ments are bound by the trans-elements in pre-mRNA 
splicing. Among the cis-elements, consensus splice 
sites are essential for pre-mRNA splicing and are 
comprised of a 5´splice site (5´SS), a branch point 
motif, a poly-pyrimidine tract ((Y)n), and a 3´splice 
site (3´SS) (Fig. 3). Among the consensus splice sites, 
the 5´SS is also known as a splice donor site and the 
3´SS is also known as a splice acceptor site. Splice 
enhancers and silencers are known as cis-regulatory 
elements, and both of these sites are important for 
the recognition of the 5´SS and 3´SS regions, and 
depending on their localization within the genome, 
splice enhancers and silencers are subclassified 
into exonic splice enhancers (ESEs), intronic splice 
enhancers (ISEs), exonic splice silencers (ESSs) 
or intronic splice silencers (ISSs). Among the known 
trans-elements, spliceosomes are multicomponent 
complexes essential for pre-mRNA splicing. ESEs 
are predominantly bound and recognized by mem-
bers of serine/arginine-rich proteins (SR proteins, 
symbolized by SRp) and SR-like proteins. However, 
heterogeneous nuclear ribonucleoproteins (hnRNPs) 
commonly bind to ESSs and ISSs. In many cases, 
hnRNPs block spliceosome assembly, thus resulting 
in exon skipping. Several of tissue-specific SR proteins 
and hnRNPs have recently been identified. Aberrant 
alternative pre-mRNA splicing in malignancies can 
be subclassified into two categories: (I) the generation 
of an aberrant splice variant as an individual transcript 
and (II) an aberrant expression profile of splice variants 
as an entire set of transcripts in malignant cells (Fig. 3). 
Fig. 2. Alternative pre-mRNA splicing. Seven types of alternative 
splicing were indicated
Fig. 3. Regulatory mechanism of alternative pre-mRNA splicing 
and its alteration in malignancies. Cis-elements are indicated 
with rectangles and trans-elements are indicated with ellipses. 
In the nucleotide sequences, Y denotes a pyrimidine (U or C) and 
R denotes a purine (G or A). ESE, exonic splice enhancer; ESS, 
exonic splice silencer; hnRNP, heterogeneous nuclear ribonu-
cleoprotein; ISE, intronic splice enhancer; ISS, intronic splice 
silencer; snRNP, small nuclear ribonucleoprotein; SR, serine/
arginine-rich protein; SS, splice site; U2AF, U2 small nuclear 
ribonucleoprotein auxiliary factor
SPLICE VARIANTS IN APOPTOTIC 
PATHWAY
Expression profiles of genes in the apoptotic path-
way can also be regulated by alternative pre-mRNA 
splicing in both normal and malignant tissues, and 
some of those, BCL2L1, BIRC5, CFLAR, and MADD, 
will be highlighted in this session (Fig. 4).
BCL2-like 1 (BCL2L1)
Apoptotic factors of the BCL2 family are classified 
into two subgroups: anti-apoptotic (e.g., BCL2, MCL1, 
and Bcl-xL) and pro-apoptotic (e.g., BAX and Bcl-xS) 
[6], and the two subgroups differ in the number and 
variety of BH domains they contain [7]. In 1993 Boise 
et al. isolated BCL2-like 1 (BCL2L1) gene which func-
tions as a BCL2-independent regulator of apoptosis 
(Fig. 1) [8], and alternative splicing resulted in two 
distinct BCL2L1 mRNA isoforms: the larger variant 
(Bcl-xL) which is similar in size and predicted structure 
to BCL2 and the smaller variant (Bcl-xS) which inhibits 
the ability of BCL2 to enhance the survival (Fig. 4 a). 
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Fig. 4. Splice variants of genes in the apoptotic pathway. (a) 
BCL2L1, (b) BIRC5, (c) CFLAR, and (d) MADD. For each of the 
genes, pre-mRNA is indicated at the top, and mature mRNAs 
are indicated in the bottom. ID numbers of mRNAs and the 
numbers of amino acids were referred to the NCBI database 
(as of June 1, 2012) 
The overexpression of Bcl-xL confers resistance 
to apoptosis (see Fig. 1); in contrast, Bcl-xS can 
induce apoptosis and alleviate multidrug resistance; 
hence the regulation of alternative splicing of the 
BCL2L1 gene has been intensely explored since the 
2000s [6, 9–21]. hnRNP F/H was reported to modu-
late the alternative splicing of BCL2L1 gene [9], and 
SC35, a member of the SR proteins family, is required 
to switch the alternative splicing profile of various 
apoptotic genes such as CFLAR, CASP8, CASP9, 
and BCL2L1, towards the expression of pro-apop-
totic splice variants [12]. Treatments with a chemical 
compound emetine dihydrochloride (CAS number: 
316-42-7) down-regulated the level of Bcl-xL mRNA 
[11]. In 2012 Michelle et al. at Universite de Sherbrooke 
(Quebec, Canada) [6] identified four cis-elements 
in exon 2 of the BCL2L1 gene which contribute to the 
splicing control: B2, B3, B1, and SB1 regions. 
Baculoviral IAP repeat containing 5 (BIRC5, 
survivin) 
In the process of apoptosis, the IAP family prevents 
apoptosis through direct caspase and pro-caspase 
inhibition (Fig. 1). The IAP family members are de-
fined by the presence of a baculovirus IAP repeat 
(BIR) domain [22, 23]; currently seven genes have 
been isolated in this family: XIAP, cIAP1, cIAP2, ILP2, 
BRUCE, BIRC5 (survivin) and livin. The IAP proteins 
are abnormally regulated and expressed in the ma-
jority of human malignancies at elevated levels, and 
an increasing amount of evidence has been recently 
accumulated regarding the effects of survivin on the 
anti-apoptotic pathway; hence survivin has been in-
vestigated as a therapeutic target for malignancies.
Several of splice variants of survivin have been 
reported (Fig. 4 b). In 2007 Sampath and Pelus 
published a detailed review on alternative splice vari-
ants of survivin [24]. It seems that the splice variant 
Sur2B was regarded as pro-apoptotic until the middle 
of 2000s; the results of recent studies, however, 
indicate different outcome [25–27]. In 2011 Huang 
et al. reported that the wild-type survivin (SurWT), 
Sur-DeltaEx3, Sur2B, and Sur-2alpha splice variants 
were significantly elevated in astrocytoma and were 
associated with tumor grade and poorer prognosis 
[26], and Vivas-Mejia’s study on taxane-resistant 
ovarian cancer cells showed that Sur-2B was more 
abundant in taxane-resistant cells than in taxane-
sensitive cells [27]. These results should be compre-
hensively organized to develop therapeutic agents 
to target the variants. Currently novel drugs targeting 
sirvivin such as LY2181308 [28] and YM155 [29] are 
under development, and recently amiloride was also 
reported to regulate alternative splicing of survivin 
as well as APAF1 and CRK [16].
CASP8- and FADD-like apoptosis regulator 
(CFLAR) 
By searching EST databases for sequences 
of FADD, which forms a death-inducing signaling com-
plex (DISC) with FAS-L, FAS, and pro-caspase-8 for 
the apoptotic pathway (Fig. 1), in 1997 Shu et al. 
reported cDNAs encoding a protein which they des-
ignated CASPER [30], and several groups simultane-
ously isolated genes such as CASH, MRIT, CLARP and 
others, all of which turned out to be a single gene. This 
gene is currently registered as CASP8- and FADD-
like apoptosis regulator (CFLAR) with several types 
of splice variants in the NCBI database (Fig. 4 c). 
CFLAR has two death effecter domains (DEDs) only, 
in contrast to FADD, which have two death domains 
(DDs), and caspase-8 and -10, both of which have two 
DEDs along with caspase domain. 
CFLAR is a major resistance factor and critical anti-
apoptotic regulator that inhibits TNF-alpha, FAS-L, and 
TRAIL-induced apoptosis (Fig. 1) as well as chemo-
therapy-triggered apoptosis in malignant cells. CFLAR 
binds to FADD and/or caspase-8 or -10 in a ligand-
dependent or ligand-independent fashion, which 
in turn prevents DISC formation and subsequent 
activation of the caspase cascade [31]. 13 distinct 
splice variants of CFLAR have been identified at the 
mRNA level [32–37], and CFLAR is expressed as long 
(c-FLIPL), short (c-FLIPS), and c-FLIPR splice variants 
in human cells (Fig. 4 c). Although CFLAR is a major 
resistance factor and critical anti-apoptotic regulator, 
the functional differences of the isoforms are still under 
exploration, and a cell-type specific pro-apoptotic role, 
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depending on caspase-8 to c-FLIPL ratio, has also 
been reported [38]. 
Mitogen-activated protein (MAP)-kinase acti-
vating death domain (MADD) 
In 1996 Chow and Lee reported the cDNA sequence 
of mitogen-activated protein (MAP)-kinase activat-
ing death domain (MADD), a novel human gene that 
is differentially expressed in normal and neoplastic 
cells [39]. MADD is implicated in cancer cell survival, 
proliferation, apoptosis, and other regulated functions 
[40]. Recently Prabhaker’s laboratory at University 
of Illinois at Chicago has published a series of their 
studies on splice variants of MADD gene and their 
association with apoptosis [41–45]. The MADD gene 
encodes at least six different splice variants (Fig. 4 d), 
of which four variants, namely IG20pa, MADD, IG20-
SV2, and DENN-SV, are expressed more ubiquitously 
[40]. Of these, MADD and DENN-SV are constitutively 
expressed, whereas the IG20pa and IG20-SV2 may 
or may not be expressed [40].
Other apoptotic genes with splice variants 
In addition, splice variants which may have differen-
tial functions on apoptosis have been reported in some 
of other genes such as RBM5 [46–48], ING family 
[49–51], androgen receptor (AR) [52–54], BRCA1 as-
sociated RING domain 1 (BARD1) [55, 56], caspase 
8 (CASP8) [57, 58], Kruppel-like factor 6 (KLF6) [59, 
60], myeloid cell leukemia sequence 1 (MCL1) [13, 
61], and spleen tyrosine kinase (SYK) genes [62, 63].
THERAPEUTIC STRATEGIES TO TARGET 
SPLICE VARIANTS
In the present article we summarized splice variants 
of genes in the apoptotic pathway. Novel technolo-
gies such as microarray have enabled us to compre-
hensively screen alternative splicing, and the recent 
advance of sequencing technology will give us more 
powerful method to understand the whole picture 
of this field [64, 65]. The research on the mechanism 
of alternative pre-mRNA splicing [66, 67] and the 
trans-elements [68] are in progress, and the in silico 
computer predictions play another important role [69, 
70] although they do not always correlate with in vitro 
and in vivo results. On the other hand, the experimental 
approaches of apoptosis and oncology are essential 
for the progress of research in this field. 
The information of apoptosis will help us develop 
new strategies of cancer therapeutics. To target splice 
variants of apoptosis-associated genes, chemical 
compounds as small molecules are as important 
as ever, and RNA interference, antisense oligonucle-
otides, and splice-switching oligonucleotides [71] 
as well as monoclonal antibodies are new strategies 
to target specific sequences. If the information of the 
apoptosis and aberrant splicing in each of malignan-
cies is integrated, it will become possible to target 
proper variants for apoptosis, and the trans-elements 
themselves can become specific targets of cancer 
therapy as well. 
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